Treffer 1 - 5 von 5 für Suche 'Almond, Chrissy', Suchdauer: 0,40s Treffer weiter einschränken
  1. 1
    Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden

    Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden von Hansson-Hedblom, Amanda, Almond, Chrissy, Borgström, Fredrik, Sly, Indeg, Enkusson, Dana, Troelsgaard Buchholt, Anders, Karlsson, Linda


    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  2. 2
    The Cost‑Effectiveness of Lorlatinib Versus Chemotherapy as a Secondor Third‑Line Treatment in Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑small‑cell Lung Cancer in Sweden

    The Cost‑Effectiveness of Lorlatinib Versus Chemotherapy as a Secondor Third‑Line Treatment in Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑small‑cell Lung Cancer in Sweden... von Nilsson, Fredrik O L, Asanin, Sandra T, Masters, Elizabeth T, Ladeluca, Laura, Almond, Chrissy, Cooper, Miranda, Smith, Sarah

    Veröffentlicht in PharmacoEconomics

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  3. 3
    Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK

    Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-Effectiveness in the UK von McCarthy, Grant, Fenu, Elisabetta, Bennett, Natalie, Almond, Chrissy

    Veröffentlicht in Advances in therapy

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  4. 4
    The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden

    The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden von Nilsson, Fredrik O. L., Asanin, Sandra T., Masters, Elizabeth T., Iadeluca, Laura, Almond, Chrissy, Cooper, Miranda, Smith, Sarah

    Veröffentlicht in PharmacoEconomics

    Volltext
    Artikel

    Zu den Favoriten
    Gespeichert in:
  5. 5
    Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-effectiveness in the UK

    Intravitreal Ranibizumab for the Treatment of Visual Impairment Due to Choroidal Neovascularization Associated with Rare Diseases: Cost-effectiveness in the UK von McCarthy, Grant, Fenu, Elisabetta, Bennett, Natalie, Almond, Chrissy

    Volltext bestellen
    Bild

    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: